1. Home
  2. WINT vs STKH Comparison

WINT vs STKH Comparison

Compare WINT & STKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WINT
  • STKH
  • Stock Information
  • Founded
  • WINT 1992
  • STKH 2018
  • Country
  • WINT United States
  • STKH Israel
  • Employees
  • WINT N/A
  • STKH N/A
  • Industry
  • WINT Biotechnology: Biological Products (No Diagnostic Substances)
  • STKH Packaged Foods
  • Sector
  • WINT Health Care
  • STKH Consumer Staples
  • Exchange
  • WINT Nasdaq
  • STKH Nasdaq
  • Market Cap
  • WINT 2.2M
  • STKH 1.9M
  • IPO Year
  • WINT 1995
  • STKH 2021
  • Fundamental
  • Price
  • WINT $0.92
  • STKH $1.18
  • Analyst Decision
  • WINT Hold
  • STKH
  • Analyst Count
  • WINT 1
  • STKH 0
  • Target Price
  • WINT $350.00
  • STKH N/A
  • AVG Volume (30 Days)
  • WINT 25.7M
  • STKH 3.2M
  • Earning Date
  • WINT 08-18-2025
  • STKH 08-29-2025
  • Dividend Yield
  • WINT N/A
  • STKH N/A
  • EPS Growth
  • WINT N/A
  • STKH N/A
  • EPS
  • WINT N/A
  • STKH N/A
  • Revenue
  • WINT N/A
  • STKH $10,000.00
  • Revenue This Year
  • WINT N/A
  • STKH N/A
  • Revenue Next Year
  • WINT N/A
  • STKH N/A
  • P/E Ratio
  • WINT N/A
  • STKH N/A
  • Revenue Growth
  • WINT N/A
  • STKH N/A
  • 52 Week Low
  • WINT $0.36
  • STKH $0.97
  • 52 Week High
  • WINT $737.44
  • STKH $17.20
  • Technical
  • Relative Strength Index (RSI)
  • WINT 54.04
  • STKH 39.45
  • Support Level
  • WINT $0.91
  • STKH $1.41
  • Resistance Level
  • WINT $1.20
  • STKH $3.59
  • Average True Range (ATR)
  • WINT 0.22
  • STKH 0.24
  • MACD
  • WINT 0.01
  • STKH -0.04
  • Stochastic Oscillator
  • WINT 23.61
  • STKH 8.02

About WINT Windtree Therapeutics Inc.

Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.

About STKH Steakholder Foods Ltd.

Steakholder Foods Ltd is engaged in transforming the alternative protein industries through its technology. The group specializes in developing and selling 3D-printing production machines, supported by proprietary premix blends, formulated from the highest-quality raw ingredients. These tools help manufacturers of all sizes efficiently produce foods that meet consumer expectations for taste, texture, and appearance and offer a safe and sustainable alternative to industrialized meat and seafood production. The company's expertise in creating alternative protein products replicating traditional meats' complex textures such as beef steaks, white fish, shrimp, and eel. It also explores the integration of cultivated cells, preparing for future advancements in food technology.

Share on Social Networks: